US 11,951,231 B2
Therapeutic agent for intervertebral disc degeneration and material for culturing inter vertebral disc cells
Takashi Yurube, Hyogo (JP); Yoshiki Takeoka, Hyogo (JP); Koichi Morimoto, Wakayama (JP); Saori Kunii, Wakayama (JP); and Kaoru Omae, Hyogo (JP)
Assigned to KINKI UNIVERSITY, Osaka (JP)
Appl. No. 16/966,226
Filed by NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Hyogo (JP); KINKI UNIVERSITY, Osaka (JP); and FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, Hyogo (JP)
PCT Filed Jan. 31, 2019, PCT No. PCT/JP2019/003494
§ 371(c)(1), (2) Date Jul. 30, 2020,
PCT Pub. No. WO2019/151444, PCT Pub. Date Aug. 8, 2019.
Claims priority of application No. 2018-015541 (JP), filed on Jan. 31, 2018.
Prior Publication US 2021/0046214 A1, Feb. 18, 2021
Int. Cl. A61L 27/24 (2006.01); A61K 38/39 (2006.01); A61L 27/50 (2006.01); A61L 27/52 (2006.01); A61L 27/54 (2006.01); A61P 19/08 (2006.01); A61P 43/00 (2006.01); C07K 1/12 (2006.01); C07K 14/78 (2006.01); C12M 1/00 (2006.01); C12N 5/00 (2006.01); C12N 5/077 (2010.01)
CPC A61L 27/24 (2013.01) [A61L 27/50 (2013.01); A61L 27/52 (2013.01); C07K 14/78 (2013.01); C12N 5/0655 (2013.01)] 6 Claims
 
1. A therapeutic agent for intervertebral disc degeneration, comprising:
Low Adhesive Scaffold Collagen (LASCol) at a concentration of 21 mg/ml or higher, and
a growth factor, wherein the growth factor is a compound selected from the group consisting of Osteogenic Protein-1 (OP-1), bFGF, TGF-β1, GDF-5, BMP2, VEGF, and IGF-1;
wherein the LASCol is in a gel state, wherein the LASCol contains a degradation product of collagen or atelocollagen in which a chemical bond between Y1 and Y2 of an al chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (A), or a chemical bond between G and X3 of an α2 chain is cleaved in an amino-terminal amino acid sequence including a triple helical domain of the collagen or atelocollagen, the sequence being shown by the following (B),
 
 (SEQ ID NO: 1)
 
 (A)-Y1-Y2-Y3-G-Y4-Y5-G-Y6-Y7-G-Y8-Y9-G-
(where G represents glycine, and Y1 to Y9 each represents an amino acid),
 
 (SEQ ID NO: 2)
 
 (B)-G-X1-X2-G-X3-X4-G-X5-X6-G-
(where G represents glycine, and X1 to X6 each represents an amino acid).